tirzepatide osa trial Obstructive sleep apnea — a condition where breathing repeatedly stops and starts during sleep — is closely linked to obesity. New late-stage clinical results show an investigational once-weekly Lilly medicine reduced Tirzepatide on obstructive sleep apnea-related

Acta 234, 137146

Pause or cancel anytime Plus, enjoy ongoing support from our world-class care team

1248 hours (median) in adults with type 2 diabetes Dose proportionality : Plasma concentrations, AUC, and Cmax increase proportionally with dose dose adjustments produce predictable changes in drug levels Steady state : Reached after approximately 45 weeks of consistent weekly dosing (45 half-lives), which is why the clinical titration schedule uses 4-week intervals at each dose level Metabolism and Elimination does not interact with cytochrome P450 enzymes , which means it has minimal risk of drug-drug interactions through that pathway

FIGURE 1 Given the role of GLP-1 in glycaemic control, the anti-apoptotic, growth-stimulating and insulin secretion-promoting effects on pancreatic -cells, the ability to re-sensitize the cellular insulin-signaling, minor side effects, good tolerance by normoglycemic patients and the fact that GLP-1 does not desensitize, synthetic GLP-1R agonists have been on the market for decades to treat type 2 diabetes mellitus (T2DM) or, more recently, to improve weight loss (Drucker, 2018)